August-24-2026

The Deputy Manager
Corporate Relationship Department
BSE Limited
P. J. Towers, Dalal Street,
Mumbai – 400001

Scrip Code: 544529
ISIN: INE15XJ01010

Dear Sir/Madam,

Sub: Intimation pursuant to Regulation 30 of the SEBI (LODR) Regulations, 2015 regarding Press Release-APTUS PHARMA LIMITED CHARTS NEXT GROWTH PHASE WITH FOCUS ON MANUFACTURING, PAN-INDIA EXPANSION AND GLOBAL MARKETS

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith a press release issued by "the Company" on the above captioned subject.

The press release contains certain forward-looking statements, which are subject to the qualifications and cautionary statement contained therein.

You are requested to take the above cited information on your records.

Thanking you,
Yours faithfully
For Aptus Pharma Limited

Hathi Tejash Maheshchandra
Digitally signed by Hathi Tejash Maheshchandra
Date: 2026.08.24 13:20:30 +05'30'

Tejash Maheshchandra Hathi
Managing Director
DIN: 03151221

APTUS PHARMA LIMITED CHARTS NEXT GROWTH PHASE WITH FOCUS ON MANUFACTURING, PAN-INDIA EXPANSION AND GLOBAL MARKETS

Ahmedabad, August 24, 2026: Aptus Pharma Limited ("Company"), presently operating predominantly through a marketing-led pharmaceutical business model, has outlined its next phase of growth focused on developing its own manufacturing capabilities, strengthening its Pan-India presence and exploring opportunities in international markets.

The Board of Directors has approved a proposal to raise ₹44.88 crore through a preferential issue of equity shares to identified investors. The proposal is subject to approval of the members at the forthcoming Annual General Meeting scheduled for September 14, 2026, and other applicable statutory and regulatory approvals.

Subject to receipt of the requisite approvals and completion of the preferential issue, the Company proposes to utilise ₹25 crore towards capital expenditure comprising land acquisition, manufacturing plant structure, hi-tech storage facilities and vehicles; ₹10 crore towards working-capital requirements; and ₹9.88 crore towards general corporate purposes, including operational requirements, corporate exigencies, strategic growth, business expansion, strengthening of the financial position, enhancement of net worth and reduction of debt. The issue proceeds are proposed to be utilised within 36 months from the date of receipt of funds, in accordance with the disclosures contained in the AGM Notice.

As part of its long-term strategy, the Company proposes to develop its own manufacturing capabilities and aspires to meet approximately 20% of its product requirements through in-house manufacturing. The initiative is expected to strengthen control over product quality, supply-chain management and product availability and support the development of its own-brand portfolio. Its implementation will be subject to commercial and technical feasibility, availability of funds and applicable regulatory approvals.

On the domestic front, the Company intends to progressively strengthen its sales and distribution presence across West, Central, East and South India as it moves towards broader Pan-India operations.

The Company also intends to explore opportunities in select international markets, including Africa, the Middle East and Latin America, through product registrations, export partnerships and other permissible business arrangements. Such expansion will be pursued progressively, subject to commercial viability, market conditions and applicable regulatory approvals.

Managing Director's Statement

Mr. Tejash Hathi, Managing Director of Aptus Pharma Limited, said:

"Our next phase is focused on developing Aptus Pharma Limited into a stronger and more integrated pharmaceutical enterprise. Our strategic direction is clear—from marketing-led operations towards manufacturing capabilities, from a regional presence towards Pan-India operations, and from domestic markets towards suitable international opportunities. Subject to the requisite approvals, the proposed ₹44.88 crore preferential issue is expected to strengthen our capital base and support capital expenditure, working-capital requirements and long-term business growth. Our aspiration to progressively meet approximately 20% of our product requirements through in-house manufacturing forms an important part of this strategy."

The proposed capital raise, development of manufacturing capabilities, strengthening of domestic operations and exploration of international markets together represent an important phase in the Company's long-term business development.

Cautionary statement

This press release contains forward-looking statements relating to the Company's strategies, objectives and proposed business plans. Actual results, outcomes and implementation timelines may differ depending upon commercial feasibility, availability of funds, market conditions and applicable statutory and regulatory approvals.